目的 磁共振灌输成像持续监测 局部进展期乳腺癌(locally advanced breast cancer,LABC)在新辅助化疗下 的疗效价值评估。方法 对33例局部乳腺 癌患者行新辅助化疗后(手术前),根据 疗效分为效应组与无效应组，对比两组 癌灶退缩率(Tumor regression rate， TRR)、最大信号衰减率（Maximum signal intensity loss rate，MSILR）以及肿瘤 灶体积(Gross tumor volume，GTV)之间 的关系。结果 行化疗术后效应组实体瘤 平均体积为(2.88±1.02)cm3 ,该数值低无 效应组,且该差异具统计学意义(P<0.05); 效应组治疗后的MSILR为(14±11.17)%， 纵向对比低于效应组化疗前 (41.51±3.5)%，横向对比低于无效组化 疗后(42.6±4.8)%;效应组(14.64±5.42) 与无效应组(7.86±3.17)患者间的灌注信 号MSILR明显变化，且该差别统计学上有 意义(P＜0.05);MSILR的均值与TRR为正相 关(r=0.320，P=0.53)。结论 磁共振灌输 加权成像(Perfusion weighted magnetic resonance imaging，PMRI)用于跟踪监测 LABC新辅助化疗疗效的临床价值可以确 认，但是否可作预后评估因子仍需要进一 步大数据的检测和分析的支持。

Objective To explore the clinical value of MR perfusion imaging technique for the early therapeutic effect with primary t chemotherapy for local advanced breast cancer and analyze the detection means as chemotherapy prognosis evaluation factor. Methods 33 cases of patients with LABC and randomly divide them into effective group and ineffective group, the data of TRR,GTV and MSILR before and after chemotherapy will be thoroughly examined.. Results The average volume of solid tumor in postoperative chemotherapy group is (2.88±1.02)cm3 ,the statistic is lower than that without chemotherapy and in ineffective group(P<0.05), the maximum signal loss rate was (14±11.17)%from effect group after treatment,which is significantly lower than the number from group before chemotherapy (41.51±3.5)% and ineffective group after chemotherapy (42.6±4.8)%.All of the data was statistically considered significant (P<0.05), The MSILR average value was positively correlated with tumor shrinking rate (r=0.313, P=0.44). Conclusion Magnetic resonance perfusion imaging technology has a certain clinical value for the early therapeutic effect monitoring tracking primary chemotherapy for local advanced breast cancer, but it still need further analysis and detection of big data support.